X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs DISHMAN PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH DISHMAN PHARMA PANACEA BIOTECH/
DISHMAN PHARMA
 
P/E (TTM) x 172.3 25.1 686.8% View Chart
P/BV x 3.8 3.3 114.4% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 PANACEA BIOTECH   DISHMAN PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
DISHMAN PHARMA
Mar-16
PANACEA BIOTECH/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs149374 39.7%   
Low Rs82129 63.8%   
Sales per share (Unadj.) Rs84.1197.8 42.5%  
Earnings per share (Unadj.) Rs-18.321.2 -86.3%  
Cash flow per share (Unadj.) Rs-6.734.7 -19.3%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs83.7179.9 46.5%  
Shares outstanding (eoy) m61.2580.69 75.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.41.3 107.9%   
Avg P/E ratio x-6.311.9 -53.2%  
P/CF ratio (eoy) x-17.27.2 -237.9%  
Price / Book Value ratio x1.41.4 98.6%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m7,07420,306 34.8%   
No. of employees `0002.80.8 331.7%   
Total wages/salary Rs m1,4495,355 27.1%   
Avg. sales/employee Rs Th1,874.119,252.7 9.7%   
Avg. wages/employee Rs Th527.06,459.5 8.2%   
Avg. net profit/employee Rs Th-407.72,064.1 -19.8%   
INCOME DATA
Net Sales Rs m5,15415,961 32.3%  
Other income Rs m100265 37.6%   
Total revenues Rs m5,25416,226 32.4%   
Gross profit Rs m-7664,103 -18.7%  
Depreciation Rs m7111,091 65.2%   
Interest Rs m1,503944 159.1%   
Profit before tax Rs m-2,8812,334 -123.4%   
Minority Interest Rs m110-   
Prior Period Items Rs m-61 -518.2%   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17624 2.7%   
Profit after tax Rs m-1,1211,711 -65.5%  
Gross profit margin %-14.925.7 -57.8%  
Effective tax rate %-0.626.7 -2.2%   
Net profit margin %-21.810.7 -202.9%  
BALANCE SHEET DATA
Current assets Rs m3,81011,018 34.6%   
Current liabilities Rs m8,3659,517 87.9%   
Net working cap to sales %-88.49.4 -939.9%  
Current ratio x0.51.2 39.3%  
Inventory Days Days156110 140.9%  
Debtors Days Days6735 193.0%  
Net fixed assets Rs m14,48016,304 88.8%   
Share capital Rs m61161 38.0%   
"Free" reserves Rs m90312,907 7.0%   
Net worth Rs m5,12714,516 35.3%   
Long term debt Rs m5,8324,189 139.2%   
Total assets Rs m19,43329,805 65.2%  
Interest coverage x-0.93.5 -26.4%   
Debt to equity ratio x1.10.3 394.1%  
Sales to assets ratio x0.30.5 49.5%   
Return on assets %2.08.9 22.0%  
Return on equity %-21.911.8 -185.5%  
Return on capital %3.617.5 20.7%  
Exports to sales %24.524.8 98.9%   
Imports to sales %10.23.7 272.6%   
Exports (fob) Rs m1,2643,956 31.9%   
Imports (cif) Rs m525596 88.0%   
Fx inflow Rs m1,5394,952 31.1%   
Fx outflow Rs m942697 135.2%   
Net fx Rs m5974,255 14.0%   
CASH FLOW
From Operations Rs m5992,786 21.5%  
From Investments Rs m-438-1,529 28.6%  
From Financial Activity Rs m-303-941 32.2%  
Net Cashflow Rs m-141316 -44.7%  

Share Holding

Indian Promoters % 74.5 61.4 121.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 3.7 16.2%  
FIIs % 1.3 12.7 10.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 22.1 106.8%  
Shareholders   10,259 46,261 22.2%  
Pledged promoter(s) holding % 35.1 35.8 98.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   WOCKHARDT LTD.  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON LTD  FULFORD INDIA  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 20, 2018 03:35 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS